Sponsors (15)
The bill lets states impose stricter bans and disclosure rules to protect local public health and transparency, but does so at the cost of regulatory fragmentation that raises compliance costs, legal complexity, and the risk of reduced product availability.
Consumers and public-health officials in states: State and local governments can restrict or ban specific cosmetic ingredients so jurisdictions can act faster or more stringently to protect local public health.
State and local governments, businesses, and consumers: States may keep existing ingredient‑reporting rules and require greater disclosure or manufacturing transparency than federal law, preserving local transparency requirements and giving consumers more information about products.
Cosmetic manufacturers (especially small businesses): Will face a patchwork of differing state rules that raises compliance costs and could drive up prices for consumers.
State and local governments and federal regulators: Differing state standards could complicate enforcement and interstate commerce and create legal uncertainty for regulators like the FDA.
Consumers in some states: May face reduced product availability if manufacturers withdraw products rather than comply with multiple state-specific requirements.
Based on analysis of 2 sections of legislative text.
Clarifies that the 2022 cosmetics modernization law does not preempt state or local rules on ingredients, reporting, or disclosure except where the federal law expressly says so.
Official title: To amend title VI of the Federal Food, Drug, and Cosmetic Act to ensure the supply chain transparency needed for companies to make safe cosmetics, and for other purposes.
Introduced July 16, 2025 by Janice D. Schakowsky · Last progress July 16, 2025
Clarifies that the Modernization of Cosmetics Regulation Act of 2022 does not broadly preempt state or local laws: states and their political subdivisions may continue to ban or limit cosmetic ingredients, keep existing ingredient-reporting rules, and impose or maintain requirements that provide greater transparency, disclosure, or protections than the 2022 law where not expressly preempted. The bill inserts additional text into Chapter VI of the Federal Food, Drug, and Cosmetic Act to record and expand those non‑preemption principles.